Paperonium

← Back to the plain-language case

Abstract swaps the retina and vitreous ranibizumab half-lives given in the Results and Discussion

Commun Biol (2020) · doi:10.1038/s42003-019-0731-9 · PMC6949284

Summary

The abstract reports half-lives for labeled ranibizumab of 3.34 days at the retina and 4.52 days in the vitreous. The Results and the Discussion both give the same two numbers the other way round: 4.52 days in the retina and 3.34 days in the vitreous. The fitted lines in Figure 6a give about 4.55 days for the retina and 3.29 days for the vitreous, so the paper's own figure agrees with the body text and the abstract has the compartment labels exchanged. The half-lives are the abstract's only quantitative result. With the abstract's labels, the vitreous value (4.52 days) falls outside the 2.6–4 day range of earlier non-human primate (NHP) studies that the Discussion uses to validate the method. With the body's labels (3.34 days) it falls inside.

What the paper reports

All quotations are verbatim from the article as archived in PMC. The superscript reference numbers that PMC flattens into the text ("days5,8,28", "ranibizumab29") are written here as superscripts.

Abstract:

Here, we show a proof-of-concept for labeled ranibizumab with observed half-lives of 3.34 and 4.52 days at the retina and in the vitreous, respectively.

Results, section "In vivo distribution of a long-acting anti-VEGF antibody in the eye", second paragraph:

Maximal ranibizumab concentrations were estimated to reach 0.1 and 0.028 mg/mL in the vitreous and retina, respectively (Fig. 6a). Further pharmacokinetic analysis showed that labeled ranibizumab exhibited a half-life and an area under the curve (AUC) of 4.52 days and 0.22 day × mg/mL in the retina. In the vitreous, the calculated half-life, AUC, clearance, and volume distribution were 3.34 days, 0.57 day × mg/mL, 0.44 mL/day, and 4.78 mL, respectively.

Discussion, second paragraph:

The pharmacokinetic analysis for ranibizumab showed a half-life of 3.34 days in the vitreous, which is consistent with half-life measured in NHPs (2.6–4 days5,8,28) and in humans for ranibizumab29 with invasive measures. By contrast, the half-life measured in the retina with this technology was higher than reported elsewhere (4.52 days as compared to 2.6–2.3 days from ref. 5).

Clearance and volume of distribution were also similar between both approaches (0.594 mL/day for clearance and 2.75 mL for volume of distribution from enzyme-linked immunosorbent assay (ELISA) as compared to 0.44 mL/day and 4.78 mL from ocular tracking).

Methods, "Data analyses":

The half-lives of labeled antibodies in the vitreous and at the retina were then measured using a non-compartmental analysis on mean concentrations for all data points tested in each compartment using at least five time points with time range between Day 2 and last Day tested as the curve fitting approach and an uniform weighting (WinNonlin, Pharsight Corp., Mountain View, CA).

From the vitreous results, clearance (CL) was calculated from the formula: CL = dose/AUC, where dose is the amount of protein injected IVT (0.25 mg)

The volume of distribution (V) was calculated from the equation: V = CL/kel, where kel is the elimination rate constant obtained from the slope of the terminal data from the concentration–time plot.

Figure 6 legend, panel a:

Pharmacokinetics in both vitreous and retina were then determined by non-compartmental analysis based on mean concentrations at 40% intensity.

What the paper's own numbers show

Method. I tabulated the half-life given to each compartment in the abstract, the Results and the Discussion. I then made three independent checks of which assignment is correct.

  1. Figure 6a plots log concentration against time for each compartment, with a fitted line. I measured the slope of each fitted line in the publisher's full-size image, calibrated against the panel's own axis ticks (decades on the y-axis, days 0 and 30 on the x-axis), and converted it to a half-life (t1/2 = ln 2 / kel).
  2. I compared each assignment with the literature ranges the Discussion cites.
  3. I checked the vitreous clearance and volume against the Methods formulas.

Every number below is printed by recompute.py.txt, which also re-measures the Figure 6a lines when given the image file.

Quantity Location Reported Recomputed from the paper's own numbers
Ranibizumab t1/2, retina Abstract 3.34 d Results and Discussion give 4.52 d (mismatch)
Ranibizumab t1/2, vitreous Abstract 4.52 d Results and Discussion give 3.34 d (mismatch)
Ranibizumab t1/2, retina Results; Discussion 4.52 d the two sections agree
Ranibizumab t1/2, vitreous Results; Discussion 3.34 d the two sections agree
Slope of fitted line, vitreous panel Figure 6a (not stated) 0.0914 decades/day, kel 0.211/day, t1/2 3.29 d
Slope of fitted line, retina panel Figure 6a (not stated) 0.0662 decades/day, kel 0.152/day, t1/2 4.55 d
Vitreous t1/2 vs NHP range 2.6–4 d Discussion "consistent with" 3.34 d is inside the range; 4.52 d is outside it
Retina t1/2 vs ref. 5 (2.3–2.6 d) Discussion "higher than reported elsewhere" 4.52 d is 1.74 times 2.6 d; 3.34 d would be 1.28 times
Vitreous clearance CL = dose/AUC Results; Methods 0.44 mL/day 0.25 / 0.57 = 0.4386 mL/day (matches)
Ratio of the two half-lives — — 4.52 / 3.34 = 1.353

Figure 6a resolves the conflict. The vitreous panel's fitted line falls by a factor of 10 about every 10.9 days, which gives a half-life of 3.29 days. The retina panel's line falls more slowly, by a factor of 10 about every 15.1 days, which gives 4.55 days. Both values are within 1.5% of the body-text numbers for the same compartment (1.42% and 0.64%). They differ from the abstract's numbers by 27% and 36%. The body text and the figure therefore agree, and only the abstract differs. Its two numbers are exactly the body's two numbers with the compartment labels exchanged.

Figure

The abstract and the body text give the same two half-lives with the retina and vitreous labels exchanged

Figure 1. The two conflicting passages. Left: the abstract sentence and the assignment it states, retina 3.34 days and vitreous 4.52 days (orange). Right: the Results and Discussion, which both state retina 4.52 days and vitreous 3.34 days (blue). The arrows follow each number from one passage to the other: each one moves to the other compartment. The right panel also gives the half-lives implied by the slopes of the fitted lines in the paper's Figure 6a (4.55 days retina, 3.29 days vitreous), measured as described above. These agree with the body text.

Only the body-text assignment matches Figure 6a and the literature comparison the Discussion makes

Figure 2. Ranibizumab half-life by compartment on a linear axis starting at zero. Orange dots: abstract. Blue dots: Results and Discussion. Open diamonds: half-life from the slope of the fitted line in Figure 6a. Grey bands: the literature ranges the Discussion compares each compartment with, 2.6–4 days in NHPs for the vitreous and 2.3–2.6 days from ref. 5 for the retina. The Figure 6a slopes sit on the body-text values. Under the body-text assignment, the vitreous value lies inside its literature band, as the Discussion says ("consistent with"). Under the abstract's assignment it lies outside.

Why it matters

Explanations considered

Status

Suggested correction

In the abstract, replace

observed half-lives of 3.34 and 4.52 days at the retina and in the vitreous, respectively

with

observed half-lives of 4.52 and 3.34 days at the retina and in the vitreous, respectively

which matches the Results, the Discussion and the fitted lines in Figure 6a. The authors may also wish to state how the vitreous volume of distribution of 4.78 mL was obtained. The Methods formula V = CL/kel gives about 2.1 mL with the reported clearance (0.44 mL/day) and vitreous half-life (3.34 days).